Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease.
Crohns Colitis 360
; 3(4): otab075, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-36777280
ABSTRACT
Background:
Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn's disease. Understanding medication adherence to oral medications in severe disease is essential.Methods:
We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Adherence was measured by proportion of days covered.Results:
Sixty-three patients were identified. All patients failed at least one prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn's disease. Significant clinical and endoscopic response was seen.Conclusion:
Adherence was high in a cohort with highly refractory disease.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article